A score test for comparing cross-sectional survival data with a fraction of non-susceptible patients and its application in clinical immunology

PLoS One. 2017 Jun 30;12(6):e0179896. doi: 10.1371/journal.pone.0179896. eCollection 2017.

Abstract

Objectives: In cross-sectional studies of time-to-event data collected by patient examinations at a single random point in time, a fraction of them will not experience the event regardless of the length of the follow-up time. This is the case in clinical immunology studies that include a mixed population, with both immune-reactive and immune-tolerant (or non-susceptible) patients. In these cases, classical tests of current status data may perform poorly. New methods for testing these data are needed.

Methods: In the two-sample comparison setting, we propose a score test for testing the null hypothesis that survival does not differ in either the non-susceptible fraction or the time-to-event distribution among the susceptible fraction.

Results: In a wide range of scenarios, simulation results show interesting improvements in power for the proposed score test compared to the logrank-type test in most of the configurations we investigated. In a cross-sectional study of drug immunogenicity among treated multiple sclerosis patients, the proposed score test reveals that gender is associated with the immunogenicity of interferon.

Publication types

  • Comparative Study

MeSH terms

  • Cross-Sectional Studies
  • Female
  • Humans
  • Male
  • Models, Theoretical
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / pathology
  • Survival Analysis*

Grants and funding

This work was supported by University Paris-Saclay (Miss Sarah Flora Jonas). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors acknowledge ABIRISK (Dr. Signe Hässler, Dr. Cyprien Mbogning). The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no [115303], resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.